Genelux Corp.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.00
- 52-Week Range
- $1.77 – $5.89
- Market Cap
- $107.66M
- P/E (TTM)
- —
- EPS (TTM)
- -0.88
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 11.09
- PEG Ratio
- —
- Return on Equity
- -273.20%
- Return on Assets
- -105.89%
- Gross Margin
- 100.00%
- Operating Margin
- -482825.00%
- Profit Margin
- 0.00%
- Current Ratio
- 1.16
- Debt/Equity
- 0.26
- Total Debt
- $2.34M
- Free Cash Flow
- $-17.27M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $99.56M
Market Snapshot
About
Genelux Corp. is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for difficult-to-treat solid tumors. The company's lead product candidate Olvi-Vec is an attenuated vaccinia virus designed to selectively infect and destroy cancer cells while stimulating an anti-tumor immune response. Genelux is advancing multiple clinical programs evaluating Olvi-Vec as monotherapy and in combination with other cancer treatments for various tumor types. The company employs proprietary platform technology to engineer viruses with tumor-selective replication capabilities.